Citations

Clear

19 citation(s) found for "Davis, Andrew".

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Gillison, Maura L. , Maghami, Ellie, Spencer, Sharon, Pfister, David G. , Birkeland, Andrew C. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Galloway, Thomas J. , Geiger, J.L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Savvides, P. , Sher, David J. , Weber, Randal S. , Weinstein, Gregory S., Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Savvides, Panayiotis S, Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Caudell, Jimmy J , Adkins, Douglas R. , Brizel, David M. , Colevas, Alexander Dimitrios , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Bruce, Justine Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 224-234

10.6004/jnccn.2022.0016 | PMID 35276673 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia
Peltenburg, Puck J. , Kallas, Dania , Bos, J. Martijn , Lieve, Krystien V.V. , Franciosi, Sonia , Roston, Thomas M. , Denjoy, Isabelle , Sorensen, Katrina B. , Ohno, Seiko , Rosés‐Noguer, Ferran , Aiba, Takeshi , Maltret, Alice , Atallah, Joseph , Giudicessi, John R. , Tanck, Michael W.T. , Kato, Koichi , Barc, Julien , Borggrefe, Martin, Behr, Elijah R. , Tfelt‐Hansen, Jacob , Zorio, Esther , Swan, Heikki, Kammeraad, Janneke A.E. , Sacher, Frédéric , Roberts, Jason D. , Berg, Maarten P. van den , Robyns, Tomas , Tavačová, Terézia , Semsarian, Christopher , Till, Jan , Horie, Minoru , Ackerman, Michael J. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Bos, Johan M , LaPage, Martin J , Atallah, Joseph , Giudicessi, J R , Clur, Sally-Ann B , Tanck, Michael , Extramiana, Fabrice , Kato, Koichi , Barc, Julien , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Zorio, Esther , Krahn, Andrew D , Davis, Andrew , Sacher, Frederic , Schwartz, Peter J. , Roberts, Jason D , Skinner, Jonathan R , van den Berg, Maarten P , Kannankeril, Prince J , Drago, Fabrizio , Robyns, Tomas , Haugaa, Kristina , Tavacova, Terezia , Semsarian, Christopher , Probst, Vincent , Brugada, Ramón , Shimizu, Wataru , Horie, Minoru , Leenhardt, Antoine , Ackerman, Michael J , Sanatani, Shubhayan , Wilde, Arthur A M , Denjoy, Isabelle , Rosés-Noguer, Ferran , Lieve, Krystien V , Peltenburg, Puck J , Ohno, Seiko , Aiba, Takeshi , Clur, Sally‐Ann B. , Blom, Nico A. , Sarquella-Brugada, Georgia , Krahn, Andrew D. , Davis, Andrew M. , Skinner, Jonathan R. , Kannankeril, Prince J. , Haugaa, Kristina H. , Leenhardt, Antoine , Werf, Christian van der

Mayo Clinic

Circulation | December 7, 2021 | Volume: 145 | Issue: 5 | Pages: 333-344

10.1161/circulationaha.121.056018 | PMID 34874747 Get It

Background: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. Methods: From 2 international registries of patients with CPVT, RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. Results: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7–15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8–12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31–3.17]; and HR, 1.99 [95% CI, 1.20–3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44–4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47–7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08–4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30–5.55]). Conclusions: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.
Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer.
D’Amico, Paolo , Zhang, Qiang , St‐Pierre, Frédérique , Zhang, Youbin , Shah, Ami N. , Davis, Andrew A. , Jacob, Saya , Vagia, Elena, Behdad, Amir , Reduzzi, Carolina , Gandini, Sara , Gerratana, Lorenzo , Qiang, Wenan , Wehbe, Firas , Curigliano, Giuseppe , Cristofanilli, Massimo

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 3036-3036

10.1200/jco.2021.39.15_suppl.3036 Get It

3036 Background: The presence of HER2 expressing (HER2+) circulating tumor cells (CTCs) occurs often in metastatic breast cancer (MBC) patients (pts). We have previously showed that the ratio among CTCs expressing high level of HER2 and the total number of HER2+ CTCs (circulating HER2 ratio, cHer2 ratio) has a prognostic role in MBC patients. Here we further investigate the role of the cHER2 ratio in the process of metastatic spread. Methods: Under IRB-approved study we prospectively analyzed blood samples of patients with MBC enrolled before starting a new line of therapy. Samples were collected from pts treated at Northwestern University (Chicago, IL) between 2016 and 2020. CTCs were enumerated through CellSearch (Menarini Silicon Biosystems, Bologna, Italy) and characterized for HER2 expression using the CellSearch CXC Kit. HER2+ CTCs were divided in 3 different categories (1+,2+,3+) leaning on fluorescence intensity. Pts with <5 CTCs (stage IV indolent) were excluded from the analysis. The cHER2 ratio, defined as the sum of 2+ CTCs and 3+ CTCs divided by the total number of HER2+ CTCs, was used to split the remaining pts in 2 different cohorts: cHER2 ratio high (> 0.75) (cHER2high) and cHER2 ratio low (≤0.75) (cHER2low). The frequency of each metastatic site (i.e. liver, lung, central nervous system, bone, lymph nodes, skin/soft tissue, serosa) and the total number of different sites involved (1-7, ≤2 and >2 sites) were compared among the two sub-populations and analyzed through Fisher exact test. Results: Out of 98 pts enrolled, 77 were classified as cHER2low and 21 as cHER2high. We observed a higher frequency of oligometastatic pts (≤2 sites involved) in the cHER2high cohort (16, 76%), compared to only 29 (37%) in the cHER2low (p<0.005). Moreover, the cHER2 ratio was associated with a tropism toward specific sites of disease spread with higher incidence of liver, lung and lymph nodes metastases in the cHER2low cohort (p<0.05). No other statistical associations were observed in respect of specific organ tropism. The frequency of involvement for each metastatic site among the two cohorts are reported in the table. Conclusions: Measuring CTCs enumeration and HER2 expression we identified two cohorts, cHER2high and cHER2low, associated with distinct patterns of metastatic spread. The cHER2low pts were correlated to multiple sites of metastatic involvement, with particular tropism toward liver, lung and lymph nodes. These results confirm the prognostic role of the cHER2 ratio, suggesting a peculiar biological meaning of the HER2+ 1+ CTCs.[Table: see text]
Initiating Pharmacologic Treatment in Tobacco-Dependent Adults
Jain, Atul , Jain, Atul, Davis, Andrew M.

Mayo Clinic

JAMA | January 19, 2021 | Volume: 325 | Issue: 3 | Pages: 301

10.1001/jama.2020.24790 | PMID 33464325 Get It

Primary Prevention of Cardiovascular Disease
Jain, Atul , Jain, Atul, Davis, Andrew M.

Mayo Clinic

JAMA | October 4, 2019 | Volume: 322 | Issue: 18 | Pages: 1817

10.1001/jama.2019.15915 | PMID 31584604 Get It

Estimating a size‐specific dose for helical head CT examinations using Monte Carlo simulation methods
Hardy, Anthony J. , Bostani, Maryam, Hernandez, Andrew M. , Zankl, M. , Cagnon, Chris H., Boone, John M. , McCollough, Cynthia, McCollough, Cynthia H. , McNitt‐Gray, Michael F.

Mayo Clinic

Medical Physics | December 19, 2018 | Volume: 46 | Issue: 2 | Pages: 902-912

10.1002/mp.13301 | PMID 30565704 Get It

PurposeSize‐specific dose estimates (SSDE) conversion factors have been determined byAAPMReport 204 to adjustCTDIvolto account for patient size but were limited to bodyCTexaminations. The purpose of this work was to determine conversion factors that could be used for anSSDEfor helical, headCTexaminations for patients of different sizes.MethodsValidated Monte Carlo (MC) simulation methods were used to estimate dose to the center of the scan volume from a routine, helical head examination for a group of patient models representing a range of ages and sizes. Ten GSF/ICRP voxelized phantom models and five pediatric voxelized patient models created from CT image data were used in this study. CT scans were simulated using a Siemens multidetector row CT equivalent source model. Scan parameters were taken from the AAPM Routine Head protocols for a fixed tube current (FTC), helical protocol, and scan lengths were adapted to the anatomy of each patient model. MC simulations were performed using mesh tallies to produce voxelized dose distributions for the entire scan volume of each model. Three tally regions were investigated: (1) a small 0.6 cc volume at the center of the scan volume, (2) 0.8–1.0 cm axial slab at the center of the scan volume, and (3) the entire scan volume. Mean dose to brain parenchyma for all three regions was calculated. Mean bone dose and a mass‐weighted average dose, consisting of brain parenchyma and bone, were also calculated for the slab in the central plane and the entire scan volume. All dose measures were then normalized by CTDIvolfor the 16 cm phantom (CTDIvol,16). Conversion factors were determined by calculating the relationship between normalized doses and water equivalent diameter (Dw).ResultsCTDIvol,16‐normalized mean brain parenchyma dose values within the 0.6 cc volume, 0.8–1.0 cm central axial slab, and the entire scan volume, when parameterized byDw, had an exponential relationship with a coefficient of determination (R2) of 0.86, 0.84, and 0.88, respectively. There was no statistically significant difference between the conversion factors resulting from these three different tally regions. Exponential relationships between CTDIvol,16‐normalized mean bone doses hadR2values of 0.83 and 0.87 for the central slab and for the entire scan volume, respectively. CTDIvol,16‐normalized mass‐weighted average doses hadR2values of 0.39 and 0.51 for the central slab and for the entire scan volume, respectively.ConclusionsConversion factors that describe the exponential relationship between CTDIvol,16‐normalized mean brain dose and a size metric (Dw) for helical head CT examinations have been reported for two different interpretations of the center of the scan volume. These dose descriptors have been extended to describe the dose to bone in the center of the scan volume as well as a mass‐weighted average dose to brain and bone. These may be used, when combined with other efforts, to develop an SSDE dose coefficients for routine, helical head CT examinations.
SCN5A mutations in 442 neonates and children: genotype–phenotype correlation and identification of higher-risk subgroups
Baruteau, Alban‐Elouen , Kyndt, Florence , Behr, Elijah R. , Vink, Arja S. , Lachaud, Matthias , Joong, Anna , Horie, Minoru , Crotti, Lia , Bos, J. Martijn , Stephenson, Elizabeth A. , Wong, Leonie C.H., Abrams, Dominic J. , Davis, Andrew M. , Winbo, Annika , Sanatani, Shubhayan , Liberman, Leonardo , Kaski, Juan Pablo , Rudic, Boris , Kwok, Sit Yee, Rieubland, Claudine, Tfelt‐Hansen, Jacob , Hare, George F. Van , Guyomarc’h-Delasalle, Béatrice, Wijeyeratne, Yanushi D. , Gourraud, Jean‐Baptiste , Marec, Hervé Le , Ozawa, Junichi , Fressart, Véronique , Lupoglazoff, Jean‐Marc, Spazzolini, Carla , Aiba, Takeshi , Tester, David J. , Zahavich, Laura , Beauséjour-Ladouceur, Virginie, Jadhav, Mangesh P. , Skinner, Jonathan R. , Franciosi, Sonia , Abdelsayed, Mena , Ruben, Peter C. , Yung, Tak‐Cheung , Ackerman, Michael J. , Wilde, Arthur A.M. , Probst, Vincent , Bos, Johan M, Crotti, Lia , Horie, Minoru , Behr, Elijah Raphael , Probst, Vincent , Bos, Johan M , Tfelt-Hansen, Jacob , Davis, Andrew , Skinner, Jonathan R , Sanatani, Shubhayan , Abrams, Dominic J , Baruteau, Alban-Elouen , Schott, Jean‐Jacques , Denjoy, Isabelle , Shimizu, Wataru , Dubin, Anne M. , Blom, Nico A. , Dagradi, Federica , Aiba, Takeshi , Krahn, Andrew D. , Schwartz, Peter J. , Kaski, Juan P , Gourraud, Jean-Baptiste , Spazzolini, Carla

Mayo Clinic

European Heart Journal | July 3, 2018 | Volume: 39 | Issue: 31 | Pages: 2879-2887

10.1093/eurheartj/ehy412 | PMID 30059973 Get It

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes
Brito, Juan P. , Montori, Víctor M. , Davis, Andrew M. , Brito, Juan P

Mayo Clinic

JAMA | February 14, 2017 | Volume: 317 | Issue: 6 | Pages: 635

10.1001/jama.2016.20563 | PMID 28196240 Get It

Population‐based analysis of prostate‐specific antigen ( PSA ) screening in younger men (
Ranasinghe, Weranja , Kim, Simon P. , Lawrentschuk, Nathan , Sengupta, Shomik , Hounsome, Luke , Barber, Jim, Persad, Raj , Jones, Richard , Davis, Paul Andrew , Bolton, Damien Michael

Mayo Clinic

BJU International | July 8, 2013 | Volume: 113 | Issue: 1 | Pages: 77-83

10.1111/bju.12354 | PMID 24053128 Get It

Objective To analyse the trends in opportunistic PSA screening in A ustralia, focusing on younger men (<55 years of age), to examine the effects of this screening on transrectal ultrasonography ( TRUS )‐guided biopsy rates and to determine the nature of prostate cancers ( PC as) being detected. Subjects and Methods All men who received an opportunistic screening PSA test and TRUS ‐guided biopsy between 2001 and 2008 in A ustralia were analysed using data from the A ustralian C ancer registry ( A ustralian I nstitute of H ealth and W elfare) and Medicare databases. The V ictorian cancer registry was used to obtain G leason scores. Age‐standardized and age‐specific rates were calculated, along with the incidence of PC a, and correlated with G leason scores. Results A total 5 174 031 PSA tests detected 128 167 PC as in the period 2001–2008. During this period, PSA testing increased by 146% (a mean of 4629 tests per 100 000 men annually), with 80 and 59% increases in the rates of TRUS ‐guided biopsy and incidence of PC a, respectively. The highest increases in PSA screening occurred in men <55 years old and up to 1101 men had to be screened to detect one incident case of PC a (0.01%). Screening resulted in two thirds of men aged <55 years receiving a negative TRUS biopsy. There was no correlation with G leason >7 tumours in patients aged <55 years. Conclusion Despite the ongoing controversy about the merits of PCa screening, there was an increase in PSA testing, especially in men <55 years old, leading to a modestly higher incidence of PC a in A ustralia. Overall, PSA screening was associated with high rates of negative TRUS ‐biopsy and the detection of low/intermediate grade PCa among younger patients.